BSG and Stroke: In order to improve the management of stroke patients, we propose that the malignant chain reaction regulated by EMMPRIN and its interacting molecules (e.g. cyclophilins, caveolins and integrins described in Section 2), and induction of potentially toxic MMPs, must be inhibited.